First patient randomized in an international double-blind Phase III cardiac surgery study

An international double-blind Phase III cardiac surgery study, sponsored by a European biopharmaceutical company and managed by GCT in Russia has got off the ground.  Recently, the leading Russian Cardiology Institute has randomized the first patient in the study.

GCT Russian team is managing regulatory, clinical, and logistics part of the clinical trial.  We are proud to contribute to this pivotal international study aimed at recruiting more than 1000 patients worldwide.